This dual mechanism (direct and secondary) likely contributes to the overall motility dysfunction observed with GLP-1 RA therapy, which can result in bowel obstruction, particularly in individuals with preexisting motility issues. This evidence concerns the gene GLP1R and intestinal obstruction.